Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Daratumumab-based therapy for newly diagnosed multiple myeloma patients with renal impairment：a multicenter retrospective study from China

View Full Paper
Ask AI
Bookmark
Share

Authors

YYYingying YeJLJun LuoHWHua Wang

Discussion

Loading...

Member takes

Overview

Multicenter retrospective study shows daratumumab improves renal and hematologic response in myeloma patients with renal impairment.

Key Points

  • Evaluate the impact of daratumumab-based therapy on renal and hematologic responses in newly diagnosed multiple myeloma patients with renal impairment.
  • Retrospective analysis of patients receiving daratumumab-based therapy.
  • Inclusion criteria: newly diagnosed multiple myeloma with renal impairment confirmed by clinical judgment or biopsy.
  • Assessment of renal and hematologic response according to IMWG criteria.
  • Follow-up determined by reverse KM method for survival analyses.
  • Renal overall response rate at 3 months was 76.4%.
  • Hematologic overall response rate at 3 months was 93.6%.
  • Median progression-free survival was 29.8 months, with median overall survival not reached.

Cite This Study

Ye et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e25bhttps://doi.org/10.1182/blood-2025-7546
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Daratumumab in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials2025 · 2 citations
  2. 2Long-Term Survival with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients—A Survey from Two Italian Centers2026
  3. 3Rapid reduction of free light chains and improvement in renal outcomes in patients with newly diagnosed multiple myeloma admitted with acute kidney injury with daratumumab-based therapy and without plasmapheresis.2024 · 2 citations
  4. 4Daratumumab‐Based Combinational Therapy as Second‐Line Treatment of Relapsed‐Refractory Multiple Myeloma: A Single‐Center Experience2025
  5. 5Daratumumab enhances the overall response to multiple myeloma therapy as the number of cycles increases2024